RET oncogene | sciencenewsnet.in

Breaking News

Glaucoma Research Foundation establishes Strategic Advisory Council

1 in 5 milk samples from grocery stores test positive for bird flu. Why the FDA says it’s still safe to drink

‘Fallout’ success: video game nostalgia spans multiple media, explains expert

Scientists are shaking up lithium extraction with a different kind of chemistry

ORNL’s Curran named Fellow of SAE, ASME

Computer Scientists Unveil Novel Attacks on Cybersecurity

Interplay between mesenchymal stem cells and macrophages: Promoting bone tissue repair

Mesenchymal stem cells and their derived exosomes for the treatment of COVID-19

Biological scaffold as potential platforms for stem cells: Current development and applications in wound healing

Effects of high glucose and severe hypoxia on the biological behavior of mesenchymal stem cells at various passages

27 Apr, 2024

Targeted Therapy Pralsetinib Safely and Effectively Treats Lung and Thyroid Cancers with RET Alterations

June 9, 2021 sarah JonasResearch Results

Results from the multi-cohort Phase I/II ARROW clinical trial, conducted by The University of Texas MD Anderson Cancer Center researchers, showed that a once-daily dose of pralsetinib, a highly selective RET inhibitor, was safe and effective in treating patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) and RET-altered thyroid cancer.